77
total announcements
543828.BO · 15 min delayed
Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries Ltd has announced the Notice of 18th Annual General Meeting to be held on 22nd September 2026.
Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries Ltd has released its Annual Report for FY 2025-26, highlighting its resilience, innovation, and commitment to delivering healthcare solutions amidst global challenges.
Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries Ltd has released its Annual Report for FY 2025-26, highlighting its resilience, innovation, and commitment to delivering healthcare solutions amidst global challenges.
Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries Ltd has announced its 18th Annual General Meeting to be held on September 22, 2026, through video conferencing. The meeting will consider the audited financial statements for the year ended March 31, 2026, and the re-appointment of Dr. Anil Ghogare as a director.
Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries Ltd has made a disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, regarding the creation of a pledge on the company's shares by persons belonging to the promoter category.
Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries Ltd has made a disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, regarding the creation of a pledge on the company's equity shares by persons belonging to the 'Promoter' category.
Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries Ltd has approved the allotment of 48,11,730 fully paid-up equity shares upon conversion of Foreign Currency Convertible Bonds (FCCBs) worth USD 15,00,000. The company's capital structure will change with the post-allotment number of shares increasing to 25,44,70,600 and issued and paid-up capital increasing to Rs. 25,44,70,600.
Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries Ltd has published the unaudited standalone and consolidated financial results for the quarter ended 30th June 2026 in the newspapers Mumbai Lakshdeep and Financial Express.
Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries Ltd submits updated Investor Presentation under Regulation 30 of SEBI LODR Regulations, disclosing company background, overview, milestones, business layout, subsidiaries, and existing products.
Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries Ltd disclosed insider trading under Regulation 31(1) and 31(2) of SEBI (SAST) Regulations, 2011, on August 14, 2026.
Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries Ltd's FCCB Committee Meeting scheduled on August 19, 2026, to consider conversion of a portion of funds raised through FCCBs into equity shares and allotment thereof.
Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries Ltd submitted a presentation on the proposed acquisition of a manufacturing plant. The plant is located 40km from Visakhapatnam Airport and spans 14 acres. It is engaged in manufacturing API and API Intermediates, with approvals from DCA, WHO, USFDA, and ANVISA. The facility has a workforce of 200 employees and operates 24/7.
Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries Ltd has approved the divestment of 2,09,100 equity shares (51.00% of paid up share capital) of Ishwari Healthcare Private Limited, a subsidiary, equivalent to 51.00% of the paid-up equity share capital of Ishwari Healthcare. Upon completion of the divestment, Ishwari Healthcare would cease to be a subsidiary of the Company.
Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries Ltd has approved the acquisition of 30% stake in its subsidiary Sudarshan Maven Pharma Private Limited for Rs. 3,000,000.
Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with a net profit of ₹604.18 lakhs and a revenue from operations of ₹16,566.03 lakhs.
Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries Ltd has made a disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, regarding the un-pledge of shares held by Mr. Hemal Mehta, a promoter of the company.
Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 12/08/2026 to consider and approve Unaudited Standalone Financial Results for the quarter ended 30/06/2026.